Spinal muscular atrophy: antisense oligonucleotide therapy opens the door to an integrated therapeutic landscape
Spinal muscular atrophy (SMA) is a devastating neuromuscular disorder characterized by loss of spinal cord motor neurons, muscle atrophy and infantile death or severe disability. It is caused by severe reduction of the ubiquitously expressed survival motor neuron (SMN) protein, due to loss of the SM...
Main Authors: | Wood, M, Talbot, K, Bowerman, M |
---|---|
Format: | Journal article |
Published: |
Oxford University Press
2017
|
Similar Items
-
Evaluation of cell-penetrating peptide delivery of antisense oligonucleotides for therapeutic efficacy in spinal muscular atrophy
by: Hammond, S, et al.
Published: (2019) -
Systemic peptide-mediated oligonucleotide therapy improves long-term survival in spinal muscular atrophy
by: Hammond, S, et al.
Published: (2016) -
Therapeutic strategies for spinal muscular atrophy: SMN and beyond
by: Bowerman, M, et al.
Published: (2017) -
Therapeutic strategies for spinal muscular atrophy: SMN and beyond
by: Bowerman, M, et al.
Published: (2017) -
A Short Antisense Oligonucleotide Ameliorates Symptoms of Severe Mouse Models of Spinal Muscular Atrophy
by: Jeffrey M Keil, et al.
Published: (2014-01-01)